BMS-986525

BMS-986525 is an investigational humanized monoclonal antibody developed by Bristol Myers Squibb for the treatment of relapsed or refractory small cell lung cancer (SCLC). It is currently being evaluated in clinical trials as a monotherapy and in combination with the anti-PD-1 checkpoint inhibitor nivolumab (Opdivo). Although the specific molecular target of BMS-986525 has not been publicly disclosed by the developer, the drug is classified as an immunotherapy designed to boost the immune system's attack on tumor cells. The clinical development program primarily targets patients who have received at least one prior platinum-based chemotherapy regimen and have progressed on or are ineligible for standard-of-care PD-1/PD-L1 inhibitor therapies.